Therapeutic nanovaccines sensitize EBV-associated tumors to checkpoint blockade therapy

Area of Science:

• Immunology
• Oncology
• Materials Science

Background:

• Successful treatment of Epstein-Barr virus (EBV)-associated tumors requires overcoming immune tolerance.
• Previous EBV vaccine research focused on effector T cells, neglecting the tumor microenvironment's immunosuppressive effects.

Purpose of the Study:

• To develop and evaluate a novel nanovaccine for EBV-associated tumors.
• To investigate the nanovaccine's impact on the tumor microenvironment and its potential to overcome immune suppression.

Main Methods:

• Manufacture of a nanovaccine using tannic acid (TA), a novel protein antigen, and CpG or interferon-α (IFN-α) as adjuvants.
• Utilized flash nanocomplexation for scalable and controllable nanovaccine formation.
• Investigated nanovaccine efficacy alone and in combination with anti-PD-L1 therapy in tumor-bearing mice.

Main Results:

• The nanovaccine, particularly when co-loaded with CpG, induced strong immune activation and inhibited tumorigenesis by targeting lymph nodes.
• Combination therapy with the nanovaccine and anti-PD-L1 significantly reduced tumor size and prolonged survival.
• The nanovaccine remodeled the tumor microenvironment by decreasing regulatory T cell infiltration.

Conclusions:

• The developed nanovaccine is a promising strategy for treating EBV-positive tumors.
• The nanovaccine can reverse immune checkpoint inhibitor resistance by modulating the tumor microenvironment.
• This approach offers a new avenue for enhancing anti-tumor immunity in patients with EBV-associated malignancies.